KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Payables (2016 - 2025)

Historic Payables for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $1.2 billion.

  • BeOne Medicines' Payables rose 28921.87% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 28921.87%. This contributed to the annual value of $1.3 billion for FY2024, which is 29875.66% up from last year.
  • BeOne Medicines' Payables amounted to $1.2 billion in Q3 2025, which was up 28921.87% from $360.8 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Payables registered a high of $1.3 billion during Q4 2024, and its lowest value of $146.9 million during Q1 2021.
  • For the 5-year period, BeOne Medicines' Payables averaged around $376.0 million, with its median value being $294.8 million (2022).
  • As far as peak fluctuations go, BeOne Medicines' Payables tumbled by 5371.91% in 2021, and later soared by 29875.66% in 2024.
  • Over the past 5 years, BeOne Medicines' Payables (Quarter) stood at $262.4 million in 2021, then increased by 12.34% to $294.8 million in 2022, then increased by 6.9% to $315.1 million in 2023, then surged by 298.76% to $1.3 billion in 2024, then dropped by 4.74% to $1.2 billion in 2025.
  • Its Payables stands at $1.2 billion for Q3 2025, versus $360.8 million for Q2 2025 and $364.5 million for Q1 2025.